Inaugural Members Include Leading Experts in Genomics and Machine Learning
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Freenome, the health technology company creating tools that empower people to prevent, diagnose, and treat their diseases, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in genomics and machine learning. The SAB will serve as strategic and scientific counsel, working closely with Freenome’s management team to advance the development of the company’s technology platform and commercial disease screening products.
“We are honored to welcome these leading experts in the fields of genomics and computational biomedicine to our newly formed Scientific Advisory Board,” said Gabe Otte, Chief Executive Officer of Freenome. “The expertise that the new SAB brings to our executive team will be invaluable in helping guide the development of our platform, as we work to bring accurate, accessible and non-invasive disease screening to doctors and their patients.”
The inaugural members include:
“Freenome is pioneering a unique approach to early disease detection and intervention and I am looking forward to working closely with them as they look well beyond traditional liquid biopsy techniques to re-invent cancer screening and treatment,” said Dr. Elemento.
“I am excited to support Freenome in developing novel computational methods that measure patients’ immune responses to cancer and other diseases,” added Dr. Kundaje. “The future of personalized medicine is inevitably connected to the future of artificial intelligence, and Freenome is leading the charge.”
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors. For more information, please visit Freenome online at: www.Freenome.com.
Colin Sanford, 415-946-1094
Freenome is a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a standard blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California.